Masimo
MASI
$178.80
+0.18%
Masimo Corporation is a medical technology company that develops, manufactures, and markets noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices, and consumer health products, operating within the Medical Instruments & Supplies industry. The company is a recognized market leader and innovator in pulse oximetry and other monitoring technologies, with a distinct competitive identity built on proprietary signal processing and sensor technologies. The current investor narrative is overwhelmingly dominated by the pending acquisition by Danaher, as evidenced by the stock's dramatic price re-rating in mid-February 2026 and recent analyst downgrades to neutral ratings, shifting the debate from fundamental execution to the certainty and terms of the deal closure.…
MASI
Masimo
$178.80
Related headlines
Investment Opinion: Should I buy MASI Today?
Rating & Thesis: Hold. The investment thesis is a binary event play where the current price fully reflects the acquisition premium, offering limited upside and asymmetric downside if the deal fails, as reflected in recent analyst downgrades to neutral ratings.
Supporting Evidence: The stock trades at 99.7% of its 52-week high ($179.0), suggesting the acquisition premium is fully priced. Its forward P/E of 27.03x is elevated for a company with negative trailing earnings and a 31% YoY revenue decline. While TTM free cash flow of $195.8M and a strong current ratio of 2.49 provide financial stability, the core business metrics do not support the current valuation standalone. The implied upside is minimal, as the price has been range-bound for months following the initial surge.
Risks & Conditions: The two biggest risks are deal failure and a deterioration in core fundamentals during the waiting period. This Hold rating would upgrade to a Buy only if the stock price meaningfully dips (e.g., below $160) on unfounded deal fears, creating a better risk/reward entry. It would downgrade to a Sell if the acquisition is formally terminated or if Q4 2026 revenue (post-divestiture) shows continued decline beyond expectations. Relative to its own volatile history and the acquisition offer, the stock is fairly valued but vulnerable.
Sign up to view all
MASI 12-Month Price Forecast
The 12-month outlook is almost entirely contingent on the Danaher acquisition. The high probability of deal success (70%) supports prices near current levels but also caps upside, creating a low-return, event-driven holding. The bear case, while low probability, carries severe downside risk of 22-29% to the pre-deal trading range. The neutral stance reflects this asymmetric risk/reward: the favorable odds of success are offset by the catastrophic outcome of failure and the lack of fundamental upside. The stance would turn bullish only if the deal spread widens significantly on temporary noise, or bearish if concrete signs of deal jeopardy emerge.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Masimo's 12-month outlook, with a consensus price target around $232.44 and implied upside of +30.0% versus the current price.
Average Target
$232.44
1 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
1
covering this stock
Price Range
$143 - $232
Analyst target range
Analyst coverage for Masimo appears limited, with data showing only one analyst providing estimates for revenue and EPS, but recent institutional rating actions provide a clearer sentiment picture. The consensus sentiment has shifted markedly to neutral following the acquisition announcement, as evidenced by downgrades from Raymond James (to Market Perform from Outperform), Wells Fargo (to Equal Weight from Overweight), and BTIG (to Neutral from Buy) in February and March 2026. These actions suggest analysts believe the deal price fairly reflects the company's value, limiting further upside. The average estimated EPS for the next period is $7.43, with a revenue estimate of $1.97 billion. Insufficient explicit price target data is available to calculate a precise implied upside or downside, but the recent stock price surge to ~$178 aligns with the acquisition premium, indicating the market has priced in the deal. The wide dispersion in analyst actions—from bullish calls in late 2025 to neutral stances post-announcement—signals high uncertainty and a transition from fundamental analysis to event-driven trading. The limited coverage and recent downgrades imply that for most investors, the stock is now a binary bet on the acquisition closing successfully.
Bulls vs Bears: MASI Investment Factors
The bull case is currently stronger, resting almost entirely on the high probability of the Danaher acquisition closing at a premium price, as evidenced by the stock's 37% surge and sustained consolidation near its 52-week high. The bear case highlights severe standalone fundamental weaknesses, including a 31% YoY revenue decline and erratic profitability. The single most important tension in the investment debate is the binary outcome of the acquisition: success locks in gains near current levels, while failure would expose the stock's overvaluation relative to its deteriorating fundamentals, likely triggering a rapid mean reversion towards its pre-announcement price near $130.
Bullish
- Acquisition Premium Priced In: The stock price surged 37% in 3 months to $178.47, just shy of its 52-week high of $179.0, following the announcement of the acquisition by Danaher. This re-rating reflects a significant control premium and the market's expectation of a successful deal closure, which offers a clear exit near current levels.
- Strong Core Profitability Metrics: Despite revenue volatility, Masimo maintains robust gross margins of 61.90% (TTM) and a solid Q4 2025 operating margin of 20.34%. This demonstrates the underlying pricing power and operational efficiency of its core healthcare technology segment, which is attractive to an acquirer.
- Healthy Balance Sheet & Cash Flow: The company has a strong current ratio of 2.49 and generated $195.8M in TTM free cash flow. This financial stability reduces deal completion risk and provides operational flexibility, supporting the acquisition narrative.
- Strategic Value to Danaher: News analysis indicates the acquisition offers Danaher steady growth and clear financial benefits. Masimo's proprietary monitoring technology and market leadership represent strategic assets that justify the premium valuation, as seen in the EV/Sales multiple of 6.22x.
Bearish
- Severe Fundamental Revenue Contraction: Q4 2025 revenue of $412.5M represents a 31.33% year-over-year decline. The multi-quarter trend shows revenue falling from $600.7M in Q4 2024, indicating significant underlying business challenges in the core healthcare segment, which reported $411.6M for the quarter.
- Erratic Profitability & Negative ROE: The company's profitability is highly inconsistent, swinging from a net loss of -$100.4M in Q3 2025 to a profit of $68.3M in Q4 2025. This volatility, coupled with a deeply negative Return on Equity of -21.01%, signals poor capital efficiency and earnings quality.
- Valuation Unsupported by Standalone Metrics: With a negative trailing EPS of -$0.022, the trailing P/E is meaningless. The forward P/E of 27.03x and EV/Sales of 6.22x are elevated and only justified by the acquisition premium. If the deal fails, a severe valuation compression is likely.
- Analyst Downgrades Post-Announcement: Multiple analysts (Raymond James, Wells Fargo, BTIG) downgraded MASI to Neutral/Market Perform following the acquisition news. This consensus shift suggests the current price fully reflects the deal's value, leaving little fundamental upside for new investors.
MASI Technical Analysis
The stock is in a powerful, sustained uptrend following a decisive breakout in mid-February 2026, with a 1-year price change of +15.60%. The current price of $178.47 sits at approximately 99.7% of its 52-week high of $179.0, indicating the stock is trading at its absolute highs, which reflects maximum bullish momentum but also suggests potential overextension and limited near-term upside without a catalyst. Prior to the breakout, the stock was in a pronounced downtrend, trading as low as $125.94, but the 3-month price change of +37.13% confirms a violent and complete trend reversal driven by M&A speculation. The 1-month price change of +4.48% is positive but significantly lags the explosive 3-month move, suggesting the initial surge has matured into a consolidation phase just below the 52-week high; this is corroborated by the price action, which has been range-bound between ~$175 and ~$178.5 for the last three months. The 52-week low of $125.94 and high of $179.0 define the stock's extreme technical range. A sustained breakout above $179.0 would signal a continuation of the acquisition-driven rally, while a breakdown below the recent consolidation support near $175 could indicate deal uncertainty or profit-taking. With a beta of 1.13, the stock is moderately more volatile than the broader market, a characteristic amplified by the single-stock event risk of the pending acquisition.
Beta
1.13
1.13x market volatility
Max Drawdown
-25.9%
Largest decline past year
52-Week Range
$126-$179
Price range past year
Annual Return
+14.9%
Cumulative gain past year
| Period | MASI Return | S&P 500 |
|---|---|---|
| 1m | +0.2% | +4.0% |
| 3m | +2.4% | +8.2% |
| 6m | +26.9% | +11.5% |
| 1y | +14.9% | +24.3% |
| ytd | +40.3% | +8.3% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
MASI Fundamental Analysis
Revenue growth has been volatile and recently negative, with the latest quarterly revenue of $412.5 million representing a significant year-over-year decline of 31.33%. This sharp drop is partly attributable to the prior-year period including revenue from the now-divested Sound United consumer audio business; however, the core healthcare segment revenue of $411.6 million for the quarter indicates the underlying business is facing challenges. The multi-quarter trend shows revenue has declined from $600.7 million in Q4 2024 to $412.5 million in Q4 2025, highlighting a major contraction as the company refocuses on its core medical technology operations. Profitability has been inconsistent, with the company reporting a net income of $68.3 million in the latest quarter (Q4 2025) following a substantial net loss of -$100.4 million in Q3 2025. The quarterly gross margin of 59.95% remains healthy and is consistent with the trailing twelve-month gross margin of 61.90%, indicating strong pricing power and product mix in its core healthcare segment. The operating margin for the latest quarter was a robust 20.34%, demonstrating that despite revenue headwinds, the company can generate solid operating profits when excluding one-time charges and restructuring costs. The balance sheet shows moderate leverage with a debt-to-equity ratio of 0.78, and the company maintains a strong current ratio of 2.49, indicating good short-term liquidity. Free cash flow generation is solid, with TTM free cash flow of $195.8 million, providing financial flexibility. However, the return on equity is deeply negative at -21.01%, primarily driven by significant net losses in recent fiscal quarters, which weighs on overall capital efficiency. The company's financial health is sufficient to operate independently, but the acquisition narrative has superseded fundamental concerns.
Quarterly Revenue
$412500000.0B
2026-01
Revenue YoY Growth
-0.31%
YoY Comparison
Gross Margin
+0.59%
Latest Quarter
Free Cash Flow
$195800000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is MASI Overvalued?
Given the trailing twelve-month net income is negative (EPS of -$0.022), the primary valuation metric selected is the Price-to-Sales (PS) ratio. Masimo's trailing PS ratio is 4.47x, while its forward valuation is better assessed through the EV/Sales multiple of 6.22x, which incorporates debt and cash. The forward PE ratio of 27.03x is also available, but it is based on estimated future profitability post-acquisition or restructuring. The significant gap between the negative trailing PE and positive forward PE implies the market is pricing in a sharp recovery in earnings, largely tied to the acquisition premium and expected synergies. Compared to industry averages, Masimo's EV/Sales of 6.22x and PS of 4.47x likely trade at a premium, given the company's niche leadership and the takeover bid, though specific sector comps are not provided in the data. The premium is justified by the strategic value Danaher places on Masimo's technology portfolio and the control premium embedded in the acquisition offer, rather than by standalone financial metrics. Historically, Masimo's valuation has been volatile; its current PS ratio of 4.47x is below the 16.55x reported for Q4 2025 in the historical ratios data, but that earlier figure was calculated at a much lower stock price. The stock is trading near its 52-week high, suggesting the market is pricing in a successful deal closure at a premium, leaving little room for error if the acquisition were to fall through.
PE
-45.1x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -19x~181x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Masimo's financials reveal significant revenue contraction, with Q4 2025 sales down 31.33% YoY to $412.5M, indicating core business headwinds beyond the divestiture of Sound United. Profitability is highly volatile, with net income swinging from a $100.4M loss to a $68.3M profit in consecutive quarters, undermining earnings predictability. While the balance sheet is stable with a debt-to-equity ratio of 0.78, the negative ROE of -21.01% reflects poor capital allocation and recurring losses that would pressure the stock absent an acquisition.
Market & Competitive Risks: The primary market risk is extreme valuation compression if the Danaher deal collapses. The stock trades at a forward P/E of 27x and an EV/Sales of 6.22x, multiples that are only sustainable due to the takeover premium. Competitive risks are secondary but present; as a pure-play medtech firm post-divestiture, Masimo is exposed to innovation cycles and pricing pressure in patient monitoring. The stock's beta of 1.13 confirms it is more volatile than the market, a trait exacerbated by its current status as an event-driven holding.
Worst-Case Scenario: The worst-case scenario is the Danaher acquisition failing due to regulatory rejection, financing issues, or a change of heart. This would remove the control premium, refocusing the market on Masimo's declining revenues and inconsistent profits. A realistic downside target would be a return to pre-announcement trading levels, around the $130-$140 range seen in early February 2026, representing a potential loss of 22-27% from the current price of $178.47. A break below that could test the 52-week low of $125.94, implying a maximum drawdown of -29%.
FAQ
The key risks are: 1) Deal Failure Risk (Severe): The acquisition by Danaher could collapse due to regulatory, financing, or other issues, potentially causing the stock to fall 22-29% to its pre-announcement range. 2) Fundamental Deterioration (High): Core healthcare revenue of $411.6M in Q4 2025 shows significant contraction; further declines could threaten the deal or the standalone business. 3) Event-Driven Volatility (Medium): The stock's beta of 1.13 indicates above-market volatility, which is magnified by the binary nature of the acquisition, leading to sharp price swings on any news. 4) Limited Upside (Medium): With the stock at its highs, analyst downgrades to Neutral suggest the risk/reward is skewed negatively.
The forecast is a function of the acquisition outcome. The base case (70% probability) sees the stock trading in a tight range of $178-$185 upon successful deal closure. The bear case (10% probability) forecasts a drop to between $125.94 (52-week low) and $145 if the deal fails. A middle, delayed-scenario base case (20% probability) sees the stock trading between $160 and $175 during extended uncertainty. The most likely scenario is the bull case, as the stock price action and analyst sentiment suggest high market confidence in the deal's completion. The key assumption is that no material obstacles arise to block the transaction.
On a standalone basis, MASI is overvalued. The company has negative trailing earnings (EPS -$0.022) and revenue that declined 31.33% YoY, yet it trades at a forward P/E of 27.03x and an EV/Sales of 6.22x. These multiples are not justified by fundamentals but by the control premium embedded in the Danaher acquisition offer. Compared to its own trading history prior to the announcement (around $130), the stock is trading at a significant premium. The market is valuing MASI based on its worth to Danaher, not its intrinsic financial performance.
MASI is a good buy only for a specific type of investor: one seeking a low-volatility, event-driven return from a likely acquisition. With the stock at $178.47 (99.7% of its 52-week high), most of the upside from the Danaher deal is already priced in, offering limited appreciation potential. The 70% probability of deal success provides a floor, but the 10% probability of deal failure carries a severe downside risk of 22-29%. Therefore, it is not a good buy for investors seeking growth, value, or high risk-adjusted returns; it is a tactical hold for merger arbitrage.
MASI is strictly a short-to-medium-term, event-driven investment. The entire thesis hinges on the closure of the Danaher acquisition, expected within the next 12 months. Post-acquisition, the stock will likely be delisted or converted. The company's volatile fundamentals (negative ROE, declining revenue) make it unsuitable as a long-term growth holding. Given its binary outcome and high event risk, the suggested minimum holding period is until deal closure, and the maximum is until a definitive outcome is known. It is not suitable for long-term investors seeking compounding growth or income, as it pays no dividend.